It is also worth noting that in the case of another well-studied radionuclide used in the treatment of metastatic prostate cancer, Radium-223, changes of the tumour marker prostate-specific antigen is not considered a reliable surrogate marker for survival [28]. This evidence concerns the gene KLK3 and metastatic prostate carcinoma.